1. Home
  2. FOA vs SABS Comparison

FOA vs SABS Comparison

Compare FOA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$21.72

Market Cap

183.8M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$4.18

Market Cap

198.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOA
SABS
Founded
2013
2014
Country
United States
United States
Employees
N/A
63
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.8M
198.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FOA
SABS
Price
$21.72
$4.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$29.75
$9.80
AVG Volume (30 Days)
81.8K
465.5K
Earning Date
03-10-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$318,296,000.00
$114,698.00
Revenue This Year
$29.44
N/A
Revenue Next Year
$14.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.58
$1.00
52 Week High
$29.58
$6.60

Technical Indicators

Market Signals
Indicator
FOA
SABS
Relative Strength Index (RSI) 36.88 45.22
Support Level $21.56 $4.27
Resistance Level $23.60 $4.68
Average True Range (ATR) 0.84 0.26
MACD -0.22 -0.03
Stochastic Oscillator 10.91 15.12

Price Performance

Historical Comparison
FOA
SABS

About FOA Finance of America Companies Inc.

Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: